Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Radiomics-based Unsupervised Clustering of Acute Multiple Sclerosis Lesions
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
3-015

Multiple sclerosis (MS) lesions exhibit substantial heterogeneity in terms of underlying pathology, anatomic location, and longitudinal evolution. Conventional MRI is sensitive to some aspects of lesion heterogeneity. Unsupervised clustering approaches may identify subtypes of acute MS lesions with specific pathologic features and help improve disease characterization and prognostication.

To leverage radiomics and machine learning to identify clusters of focal acute MS lesions exhibiting similar spatial and/or textural patterns on conventional cross-sectional (pre- and post-contrast) T1-weighted, T2-weighted, PD-weighted and FLAIR brain MRIs.

Brain MRIs from the ADVANCE trial (1,512 patients with relapsing-remitting MS, NCT00906399) were retrospectively analysed. For each scan, focal acute (gadolinium-enhancing and/or new or substantially enlarging) T2 lesions (N=3058) were identified in the white matter (WM). Each lesion was represented via its center of mass in standard ICBM-152 space and radiomics-based textural properties. Similar lesions were grouped together via k-means clustering, applied separately across the spatial and each sequence-specific textural domain. Cluster count was optimized based on the silhouette score, Davies-Bouldin index and Variance Ratio Criterion.

Optimal clustering quality resulted in 8 prototypical WM sites of lesion emergence, 3 prototypical textural patterns on each of post-contrast T1-, PD-weighted and FLAIR MRI and 5 patterns on each of pre-contrast T1- and T2-weighted MRI. Statistically significant cross-sectional associations were found between the occurrence of these lesion subtypes and patient age, sex, years since disease onset and EDSS score, via logistic regression analysis (p < 0.05).

Specific spatial and textural patterns of acute MS lesions were identified using unsupervised clustering. Further work will evaluate the clinical relevance of identified acute MS lesion patterns towards predicting clinical and MRI endpoints of disease progression. The longitudinal dynamics of each lesion pattern will be investigated via measurements of future lesion repair or transition towards chronic active/inactive lesion states.

Authors/Disclosures
Bastien Cyprien Caba (Biogen Canada)
PRESENTER
Mr. Caba has received personal compensation for serving as an employee of Therapanacea. Mr. Caba has received personal compensation for serving as an employee of Biogen. Mr. Caba has received personal compensation in the range of $50,000-$99,999 for serving as a Research Engineer with Therapanacea. Mr. Caba has received personal compensation in the range of $100,000-$499,999 for serving as a Scientist II, ML/AI with Biogen.
Arie Gafson, MD, PhD (Biogen) Dr. Gafson has stock in Biogen.
Despoina Ioannidou, PhD (Therapanacea) Dr. Ioannidou has received personal compensation for serving as an employee of Therapanacea.
Phoebe Jiang, PhD Dr. Jiang has received personal compensation for serving as an employee of Biogen. Dr. Jiang has stock in Biogen.
Elizabeth Fisher Elizabeth Fisher has received personal compensation for serving as an employee of Biogen. Elizabeth Fisher has stock in Biogen. Elizabeth Fisher has received intellectual property interests from a discovery or technology relating to health care.
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Celgene. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has stock in NeuroRx.
Colm Elliott (NeuroRx Research) Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research.
Nikos Paragios (TheraPanacea) Nikos Paragios has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZeneca. Nikos Paragios has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Nikos Paragios has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for ArteDrone. Nikos Paragios has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Nikos Paragios has received intellectual property interests from a discovery or technology relating to health care. Nikos Paragios has received personal compensation in the range of $100,000-$499,999 for serving as a CEO with TheraPanacea.
Shibeshih Belachew, MD Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.